Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices 27627 

1Handbook for Electronic Filing Procedures: 

https://www.usitc.gov/documents/handbook_on_

filing_procedures.pdf. 

United States agents or distributors for 

certain magnetic data storage tapes and 

cartridges containing the same that 

infringe the ’891 patent. 

On May 9, 2018, Fujifilm filed a 

complaint requesting that the 

Commission institute a formal 

enforcement proceeding under 

Commission Rule 210.75 to investigate 

alleged violation of the CDOs by Sony. 

On May 23, 2018, Sony filed a letter 

requesting that the Commission 

determine not to institute the 

enforcement proceeding. On May 30, 

2019, Fujifilm filed a response. 

Having examined the enforcement 

complaint, the supporting documents, 

and the pre-institution correspondence, 

the Commission has determined to 

institute a formal enforcement 

proceeding, pursuant to 19 CFR 

210.75(a), to determine whether a 

violation of the March 8, 2018 CDOs 

issued in the original investigation has 

occurred and to determine what, if any, 

enforcement measures are appropriate. 

The named respondents are the three 

Sony entities from the original 

investigation and Sony Storage Media 

Solutions Corporation of Tokyo, Japan; 

Sony Storage Media Manufacturing 

Corporation of Miyagi, Japan; Sony 

DADC US Inc. of Terre Haute, Indiana; 

and Sony Latin America Inc. of Miami, 

Florida. OUII is also named as a party. 

The Commission has not ruled on the 

issues raised in the pre-institution 

correspondence submitted by the 

parties. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended (19 U.S.C. 1337), and in Part 

210 of the Commission’s Rules of 

Practice and Procedure (19 CFR part 

210). 

By order of the Commission. 

Issued: June 7, 2018. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2018–12655 Filed 6–12–18; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

Notice of Receipt of Complaint; 

Solicitation of Comments Relating to 

the Public Interest 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the U.S. International Trade 

Commission has received a complaint 

entitled Certain Convertible Sofas and 

Components Thereof, DN 3321; the 

Commission is soliciting comments on 

any public interest issues raised by the 

complaint or complainant’s filing 

pursuant to the Commission’s Rules of 

Practice and Procedure. 

FOR FURTHER INFORMATION CONTACT: Lisa 

R. Barton, Secretary to the Commission, 

U.S. International Trade Commission, 

500 E Street SW, Washington, DC 

20436, telephone (202) 205–2000. The 

public version of the complaint can be 

accessed on the Commission’s 

Electronic Document Information 

System (EDIS) at https://edis.usitc.gov, 

and will be available for inspection 

during official business hours (8:45 a.m. 

to 5:15 p.m.) in the Office of the 

Secretary, U.S. International Trade 

Commission, 500 E Street SW, 

Washington, DC 20436, telephone (202) 

205–2000. 

General information concerning the 

Commission may also be obtained by 

accessing its internet server at United 

States International Trade Commission 

(USITC) at https://www.usitc.gov. The 

public record for this investigation may 

be viewed on the Commission’s 

Electronic Document Information 

System (EDIS) at https://edis.usitc.gov. 

Hearing-impaired persons are advised 

that information on this matter can be 

obtained by contacting the 

Commission’s TDD terminal on (202) 

205–1810. 

SUPPLEMENTARY INFORMATION: The 

Commission has received a complaint 

and a submission pursuant to § 210.8(b) 

of the Commission’s Rules of Practice 

and Procedure filed on behalf of Sauder 

Manufacturing Company on June 7, 

2018. The complaint alleges violations 

of section 337 of the Tariff Act of 1930 

(19 U.S.C. 1337) in the importation into 

the United States, the sale for 

importation, and the sale within the 

United States after importation of 

certain convertible sofas and 

components thereof. The complaint 

names as a respondent: Krug, Inc. of 

Canada. The complainant requests that 

the Commission issue a limited 

exclusion order, a cease and desist 

order, and impose a bond upon 

respondents’ alleged infringing articles 

during the 60-day Presidential review 

period pursuant to 19 U.S.C. 1337(j). 

Proposed respondents, other 

interested parties, and members of the 

public are invited to file comments, not 

to exceed five (5) pages in length, 

inclusive of attachments, on any public 

interest issues raised by the complaint 

or § 210.8(b) filing. Comments should 

address whether issuance of the relief 

specifically requested by the 

complainant in this investigation would 

affect the public health and welfare in 

the United States, competitive 

conditions in the United States 

economy, the production of like or 

directly competitive articles in the 

United States, or United States 

consumers. 

In particular, the Commission is 

interested in comments that: 

(i) Explain how the articles 

potentially subject to the requested 

remedial orders are used in the United 

States; 

(ii) identify any public health, safety, 

or welfare concerns in the United States 

relating to the requested remedial 

orders; 

(iii) identify like or directly 

competitive articles that complainant, 

its licensees, or third parties make in the 

United States which could replace the 

subject articles if they were to be 

excluded; 

(iv) indicate whether complainant, 

complainant’s licensees, and/or third 

party suppliers have the capacity to 

replace the volume of articles 

potentially subject to the requested 

exclusion order and/or a cease and 

desist order within a commercially 

reasonable time; and 

(v) explain how the requested 

remedial orders would impact United 

States consumers. 

Written submissions must be filed no 

later than by close of business, eight 

calendar days after the date of 

publication of this notice in the Federal 

Register. There will be further 

opportunities for comment on the 

public interest after the issuance of any 

final initial determination in this 

investigation. 

Persons filing written submissions 

must file the original document 

electronically on or before the deadlines 

stated above and submit 8 true paper 

copies to the Office of the Secretary by 

noon the next day pursuant to § 210.4(f) 

of the Commission’s Rules of Practice 

and Procedure (19 CFR 210.4(f)). 

Submissions should refer to the docket 

number (‘‘Docket No. 3321) in a 

prominent place on the cover page and/ 

or the first page. (See Handbook for 

Electonic Filing Procedures, Electronic 

Filing Procedures).1 Persons with 

questions regarding filing should 

contact the Secretary (202–205–2000). 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 


amozie on DSK3GDR082PROD with NOTICES1
27628 Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices 

2All contract personnel will sign appropriate 

nondisclosure agreements. 

3Electronic Document Information System 

(EDIS): https://edis.usitc.gov. 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All such requests 

should be directed to the Secretary to 

the Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) By the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. Appendix 3; or (ii) by U.S. 

government employees and contract 

personnel,2 solely for cybersecurity 

purposes. All nonconfidential written 

submissions will be available for public 

inspection at the Office of the Secretary 

and on EDIS.3

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and of §§ 201.10 and 210.8(c) of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 201.10, 210.8(c)). 

By order of the Commission. 

Issued: June 7, 2018. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2018–12651 Filed 6–12–18; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Alcami 

Wisconsin Corporation 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before August 13, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

delegated to the Assistant Administrator 

of the DEA Diversion Control Division 

(‘‘Assistant Administrator’’) pursuant to 

section 7 of 28 CFR part 0, appendix to 

subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on May 

3rd, 2018, Alcami Wisconsin 

Corporation, W130 N10497 Washington 

Dr., Germantown, WI 53022 applied to 

be registered as a bulk manufacturer of 

the following basic classes of controlled 

substances: 

Controlled 

substance Drug code Schedule 

Thebaine ........... 9333 II 

Alfentanil ........... 9737 II 

The company plans to provide bulk 

active pharmaceutical ingredient to 

support clinical trials. 

Dated: June 6, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–12684 Filed 6–12–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Gazelle A. Craig, D.O.; Decision and 

Order 

On September 20, 2017, the Acting 

Assistant Administrator, Diversion 

Control Division, Drug Enforcement 

Administration (hereinafter, DEA or 

Government), issued an Order to Show 

Cause to Gazelle A. Craig, D.O. 

(hereinafter, Respondent), of Houston, 

Texas. GX 2 (Order to Show Cause). The 

Show Cause Order proposed the 

revocation of Respondent’s Certificate of 

Registration on the ground that she does 

‘‘not have authority to handle controlled 

substances in the State of Texas, the 

[S]tate in which . . . [she is] registered 

with the DEA.’’ Id. at 1 (citing 21 U.S.C. 

823(f) and 824(a)(3)). 

As to the Agency’s jurisdiction, the 

Show Cause Order alleged that 

Respondent holds DEA Certificate of 

Registration No. FC1384306, which 

authorizes her to dispense controlled 

substances in schedules II through V as 

a practitioner, at the registered address 

of Gulfton Community Health Center, 

6306 Gulfton St., Suite 101, Houston, 

Texas 77081. Id. The Show Cause Order 

alleged that this registration expires on 

August 31, 2018. Id. 

As the substantive ground for the 

proceeding, the Show Cause Order 

alleged that Respondent is ‘‘without 

authority to handle controlled 

substances in the State of Texas, the 

[S]tate in which . . . [she is] registered 

. . . with the DEA.’’ Id. It further 

alleged that, on July 28, 2017, the Texas 

Medical Board temporarily suspended 

Respondent’s medical license and that 

the Texas Medical Board order remains 

in effect. Id. The Show Cause Order 

asserted that Respondent is ‘‘required to 

possess authority from a [S]tate in order 

to obtain or retain a DEA 

Registration. . . . [and c]onsequently, 

the DEA must revoke . . . [her 

registration] based upon [her] lack of 

authority to handle controlled 

substances in the State of Texas.’’ Id. at 

1–2. 

The Show Cause Order notified 

Respondent of her right to request a 

hearing on the allegations or to submit 

a written statement while waiving her 

right to a hearing, the procedures for 

electing each option, and the 

consequences for failing to elect either 

option. Id. at 2 (citing 21 CFR 1301.43). 

The Show Cause Order also notified 

Respondent of the opportunity to 

submit a Corrective Action Plan. Id. at 

2–3 (citing 21 U.S.C. 824(c)(2)(C)). 


amozie on DSK3GDR082PROD with NOTICES1